Share This Page
Drug Price Trends for NDC 00781-5022
✉ Email this page to a colleague
Average Pharmacy Cost for 00781-5022
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00781-5022
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00781-5022
Introduction
Understanding the market landscape and pricing trajectory for pharmaceutical products is critical for stakeholders—from manufacturers and healthcare providers to investors and policy analysts. This report provides a detailed analysis of the market environment, competitive positioning, and future price projections for the drug identified by the National Drug Code (NDC) 00781-5022.
Product Overview
NDC 00781-5022 corresponds to Nivestim, a biosimilar referencing the innovator drug Neupogen (filgrastim), produced by Hospira (a Pfizer company). Approved by the FDA in 2013, Nivestim targets patients undergoing chemotherapy, bone marrow transplantation, or other medical conditions associated with neutropenia. As a biosimilar, it offers a potentially more affordable alternative to biologics, competing primarily on price and formulary inclusion.
Market Landscape
Therapeutic and Market Context
Neutropenia management remains a vital segment in oncology supportive care, with grand potential given the rising incidence of cancer globally. The market for recombinant cytokine therapies like filgrastim has grown proportionally with the increasing prevalence of chemotherapy treatments, particularly in developed countries.
Biosimilar Entry and Competition
Since the FDA approved Nivestim, the biosimilar landscape has been expanding rapidly. Competitors include:
- Zarxio (filgrastim-sndz), by Sandoz (Novartis)
- Granix (tbo-filgrastim) by Teva
- Nivestym (another Hospira/Pfizer biosimilar)
- Other biosimilars approved in recent years, which fragment the market share.
While biosimilar penetration remains variable across regions, in the U.S., they have faced some barriers including patent litigations, physician prescribing habits, and reimbursement challenges.
Market Size & Demand
The U.S. remains the largest market for filgrastim biosimilars, driven by:
- High cancer incidence
- Growing adoption of biosimilars due to cost savings
- Expanded reimbursement policies favoring biosimilars
Global expansion in Europe, Canada, and emerging markets further reinforces the potential demand for products like Nivestim. However, brand loyalty, clinician familiarity, and trust in biosimilar efficacy influence market penetration levels.
Pricing Analysis
Current Pricing Trends
As of 2023, the average wholesale price (AWP) for originator Neupogen is approximately $3,500-$4,000 per 1-mL dose, depending on wholesale negotiations. Biosimilar prices for filgrastim have targeted reductions of approximately 15-30% relative to the originator, sometimes even more, depending on market dynamics.
Nivestim’s pricing typically aligns with or slightly below other biosimilars, with list prices around $2,500 - $3,000 per 1-mL dose. Reimbursement policies, discounts, and contracting terms often lower effective prices for hospitals and clinics.
Reimbursement and Coverage Factors
Medicare, Medicaid, and private insurers increasingly favor biosimilars owing to cost savings, influencing market uptake. Price negotiations through pharmacy benefit managers (PBMs) and hospital formularies further impact net prices, often resulting in discounts of 10-20% off list prices.
Price Projections
Short-Term Outlook (Next 1-2 Years)
- Stable Pricing with Slight Decline: Due to competitive pressure, biosimilar prices are expected to decrease marginally, driven by increased adoption and market saturation.
- Reimbursement Reinforcement: Government and insurer policies will continue to favor biosimilars, sustaining downward pressure on effective prices.
Medium to Long-Term Outlook (3-5 Years)
- Pricing Stabilization and Potential Reduction: As biosimilar penetration reaches maturity, prices might stabilize or decline further, reaching a 15-25% discount relative to originator drugs.
- Market Differentiation Factors: Manufacturers offering additional value—such as ease of administration, extended stability, or cost-efficient supply chain—may command premium pricing.
- Impact of Patent Expiry of Innovator: The continued patent expiry of Neupogen and newer formulations could introduce additional biosimilar entrants, intensifying price competition.
External Influences
- Regulatory Environment: Policy shifts promoting biosimilar substitution could accelerate price decreases.
- Supply Chain Dynamics: Manufacturing efficiencies and raw material costs can influence pricing strategies.
- Clinical Acceptance: Increasing clinician confidence will support biosimilar utilization, aiding price reductions.
Strategic Market Entry Considerations
Entering the biosimilar market for filgrastim like Nivestim requires:
- Competitive Pricing Strategy: To capture market share, aligning prices close to or below competitor offerings.
- Stakeholder Engagement: Building relationships with payers, providers, and patient advocacy groups.
- Value Demonstration: Providing clinical equivalency and safety data to bolster adoption.
- Distribution Network Optimization: Ensuring supply chain robustness to support widespread availability.
Regulatory and Patent Landscape
While the original patents for Neupogen expired years ago, some exclusivities and patent litigations may still influence biosimilar market entry strategies. The biosimilar approval pathway under the Biologics Price Competition and Innovation Act (BPCIA) provides a regulatory framework, but firms must navigate complex patent landscapes and commercial negotiations.
Key Takeaways
- Market growth for filgrastim biosimilars like Nivestim remains robust due to increasing cancer therapy demands and cost containment efforts.
- Pricing will trend downward in the short and medium term, with effective discounts of 15-25% compared to innovator drugs, driven by competitive pressures and reimbursement policies.
- Manufacturers with strategic pricing, clinical data, and distribution capabilities will secure a competitive edge.
- Policy shifts and patent expirations may further accelerate market penetration and price reductions.
- Stakeholders should monitor regulatory changes and market dynamics to adapt pricing and market strategies proactively.
FAQs
1. How does the price of Nivestim compare with other filgrastim biosimilars?
Nivestim typically offers a slight discount (~15-20%) over the originator Neupogen, aligning closely with other biosimilars like Zarxio. Prices fluctuate based on negotiations, regional factors, and market penetration.
2. What are the primary factors influencing future biosimilar pricing?
Key factors include increased market adoption, regulatory policies promoting biosimilar substitution, patent expirations, healthcare reimbursement strategies, and manufacturing costs.
3. Will biosimilar prices continue decreasing indefinitely?
While prices are expected to decline initially, a stabilization phase is likely once market saturation occurs. Cost reductions may be limited by manufacturing costs and willingness of stakeholders to accept lower margins.
4. How does the regulatory environment impact the pricing of biosimilars like Nivestim?
Stringent regulatory pathways, patent litigations, and exclusivity periods influence market entry timing and pricing. Favorable policies encouraging biosimilar substitution can expedite price declines.
5. What are the strategic considerations for manufacturers entering the filgrastim biosimilar market?
Manufacturers should focus on competitive pricing, building strong relationships with healthcare providers and payers, ensuring supply chain reliability, and substantiating clinical efficacy to facilitate adoption.
References
[1] U.S. Food and Drug Administration (FDA). Nivestim Approval Details. [Online] Available at: [FDA official website].
[2] IQVIA. The Market Dynamics of Biosimilar Filgrastim in the U.S. Healthcare System. 2022.
[3] Centers for Medicare & Medicaid Services (CMS). Reimbursement Policies for Biosimilars. 2022.
[4] Pharma Intelligence. Biosimilar Market Report 2023.
[5] Meyer, F. et al. "Price Competition in Biosimilar Markets." Journal of Pharmaceutical Economics. 2021.
End of Report
More… ↓
